Sign in Subscribe
Cancer research

Breakthrough in Cancer Gene Therapy: Overcoming Immune Resistance in Advanced Esophageal Squamous Cell Carcinoma

Strategic Insights

— 1 min read

Researchers at the Affiliated People's Hospital in Fujian, People's Republic of China, have reported a significant breakthrough in cancer gene therapy, using a genetically modified oncolytic adenovirus called H101 to treat advanced esophageal squamous cell carcinoma (ESCC). The study, published in Frontiers in Immunology, demonstrated the efficacy of combining H101 with chemotherapy and immunotherapy in patients with recurrent lymph node metastasis.

Key Takeaways:

  • Advanced ESCC has a poor prognosis, and effective treatment modalities need to be explored to overcome immune resistance.
  • H101, a genetically modified oncolytic adenovirus, has shown clinical efficacy in treating nasopharyngeal carcinoma and hepatocellular carcinoma.
  • In a case report, a patient with multiple relapses of advanced ESCC exhibited a progression-free survival (PFS) of 30 months following the administration of H101 in conjunction with chemo- and immunotherapy.
  • The patient experienced transient fever, lymph nodes at both injection and non-injection sites subsided, and pathological complete response was achieved after two relapsed H101 treatments.
  • Intralymphatic injection of H101 combined with chemotherapy and immunotherapy may represent a promising clinical strategy for advanced ESCC patients with recurrent lymph node metastasis.
  • The study observed significant increases in the expression of CD3, CD4, CD8, CD20, and IL-1b after two relapsed H101 treatments based on multiplex immunofluorescence analysis.

Statistics:

  • 15.5 months: progression-free survival (PFS) following the administration of first-line chemotherapy in conjunction with immunotherapy.
  • 29.1 x 12.9 mm: size of the left cervical lymph node before H101 injection.
  • 24.6 x 10.36 mm: size of the left cervical lymph node 25 days post-H101 injection.
  • 30 months: PFS after two relapsed H101 treatments.
  • 53: page number of the news report in Immunotherapy Weekly.

Sources:

  • "Overcoming immune resistance in advanced esophageal squamous cell carcinoma with recombinant human adenovirus type 5 by impacting the immune microenvironment: a case report." Frontiers in Immunology, 2025, 16.
  • Immunotherapy Weekly. July 16, 2025; p 53.

Read more